# PFL-241

Source: https://onco.cc/drugs/pfl-241/  
OnCo record `pfl-241` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

PFL-241 is an experimental small molecule kinase inhibitor from Antares Therapeutics, in phase 1 trials for non-small cell lung cancer resistant to EGFR tyrosine kinase inhibitors.

## Summary

PFL-241 (STX-241) is a small molecule kinase inhibitor from Antares Therapeutics, with Pierre Fabre Laboratories as licensee. A mutant-specific, brain-penetrant fourth-generation EGFR inhibitor meant to address the C797S resistance mutation in non-small cell lung cancer. Its furthest stage is phase 1, for non-small cell lung cancer resistant to EGFR tyrosine kinase inhibitors. ClinicalTrials.gov registers it in one study linked below. Phase 1/2 NCT06567015 recruiting, sponsored by Pierre Fabre Medicament. Whether it works in people has not been established unless a trial below reports it.

## Fields

- Kind: Treatment
- Status: phase-1
- Last checked: 2026-11-03
- Also known as: STX-241
- Tags: pipeline; ctgov-ingest
- Code: PFL-241
- Modality: Small molecule kinase inhibitor
- Mechanism: A mutant-specific, brain-penetrant fourth-generation EGFR inhibitor meant to address the C797S resistance mutation in non-small cell lung cancer.

## Sources

- Antares Therapeutics: biospace.com: https://www.biospace.com/press-releases/pierre-fabre-laboratories-strengthen-r-d-portfolio-and-announce-the-acquisition-of-the-worldwide-rights-for-pfl-721-and-pfl-241
- Antares Therapeutics: clinicaltrials.gov: https://clinicaltrials.gov/api/v2/studies/NCT06567015
- ClinicalTrials.gov: trials of PFL-241: https://clinicaltrials.gov/search?intr=PFL-241

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- targets: [EGFR](https://onco.cc/targets/egfr/)
- companies: [Antares Therapeutics](https://onco.cc/companies/antares-therapeutics/), [Pierre Fabre](https://onco.cc/companies/pierre-fabre/)
- trials: [Study of FIH of STX-241 in Locally Advanced or Metastatic NSCLC Resistant to EGFR TKIs](https://onco.cc/trials/nct06567015/)

---
JSON: https://onco.cc/api/v1/entities/pfl-241.json